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The management of acute mywardial infarction has been 
evolving rapidly since 1980. The results of experimental and 
clinical studies have caused B growing consensus that reper- 
fusion ofan occluded coronary artcry. performed in the first 
few hours of evolving acute myocardial infarction. often 
reduces early monality and reduces infarct size. For many 
teaeons. the use of thrombolytic therapy in patients with 
acute myocardial infarction has altered the way in which we 
evaluate and care for these patients. It is the purpose of this 
editorial to recommend changer in the mutine evaluation 
and care of patients with suspected acute myocardial infarc- 
tion to provide for the safe and effective use of this new 
therapy. 
Current status of thmmbdytic therapy. Studies using 
rtrwtokinase have Dmvided mat of our current clinical 
experience, although recombinant issue-type plasminogcn 
activator @t-PA). a relatively fibrin-specific agent with a 
superior coronary recanalization rate, is under intensive 
investigation and has recently been made available for 
general use (I). Several randomized trials (2-4) have re- 
ported both the efficacy and benefit associated with intraco- 
ronary streptokinase. The importance of these early findings 
is not inconsequential: however, the inherent delay in initi- 
ating therapy with intracomnary treatment makes this ap- 
pmach impractical for mat clinical situations. Intravenous 
admtnirtration obviates this problem. Recently, the results 
of two large intravenous thmmbolytic therapy trials fmm 
Europe have been reported (5-8). The GISSI (Gntppo Itaa- 
liano per lo Studio della Streptochittaai nell’lnfarto) study 
(51, a large trial enrolling 11,806 patients, demonstrated a
highly significant 18% reduction in 21 day mortality overall 
among patients treated with streptokinase within 12 h of the 
onset of chest pain. Mortality was reduced by 23% it. those 
treated within 3 hand by an astonishing 47% in those treated 
within I h. This benefit from therapy has recently been 
demonstrated to be sustained for at least I year (6). The 
ISAM (Intravenous Streptokinase in Acute Myocardial In- 
farction) trial (7) in Germany enmlkd 1,741 relatively low 
risk patients: it demonstrated a 12% reduction overall in 21 
day htortality and a 20% reduction in those patients treated 
with streptakinase within 3 h of the onset of symptoms; 
however, these differences were not statistically significant. 
Most recently, the second international study of infarct 
survival (ISIS-2 trial) (9) reported a 33% reduction in mar- 
tality (from about 12% to 8%) in the nearly 4,tXtO patients 
randomized to intravenous treptokinase within 4 h of the 
onset of symptoms as compared with control patients. It 
seems clear from these studies, as well as other abserva- 
tians, that patients with attterior myocardial infarction hen- 
efit nwst from coronary rawfusion. No study mtblished to 
date has been sudicienily l&e to demonstrateareduction i
mortality in patients with inferior myocardial infarction. 
Thrombolytic therapy plus attgioplssty. Preliminary re- 
suits from the TIMI (fhmmbolysis in Myocardial Infarction) 
Phase 1 study (I) suggest hat rl-PA results in reperfusion in 
about two-thirds of patients judged by coronary &ographv 
90 min after intravenous therapy. One-third db not respond 
to this treatment and two-thirds ofthose successfullv treated 
are left with a coronary stenosis 275%. In addition, a 
subslantial portion of patients experience recurrent signs of 
ischemia on the first day after thrombolytic therapy and a 
15% me of early coronary reocclusion has been dcmon- lent pm-hwpilill care. patients with acute myocardial infarc- 
strated. These latter findings bavc been a stimulus to study non must anivc at the bosital in optimal condition. At 
other methods of reperfusion. particularly coronary angio- present. there are relatively few cardiologists who work 
plasly, which may be used alone or in conjunction wth directly in edher paramedic management or training or who 
thmmbolytic treatment in an attempt to achieve coronary provide reguier soppon to noncardiologist emergency med- 
reprfusion in patients who have unsuccewful mtravenouc ical rerwce dtreclorctbe perrons ultimately responsible for 
thrombolytic therapy. 89 well 89 in those who are left wfb a the treatment delivered by these pre-hospital systems. Car- 
high grade residual stenosis. The use ofcoronary angiopla~ty diologwts must become more intimately involved with the 
in the setting of acute myocardial mfarction IS currently actIvitie( of the emergency system directors in each commo- 
under intense investigation. but early and late success ofthis mty m order to update treatment and triage plans so that 
invasive and expensive treatment is not yet established (10. coronary reperfusion therapy will benefit as many patients as 
II). possible. The program must take into account the local 
To achieve the beneficial results of thrombolytic therapy, geography and distribution of hospital facilities and recog- 
a well organized and efficient community emergency care niLe the need for transfer of a well defined subset of acutely 
rystem is required. Without such a system, any attempt to ill patients fmm less specialized hospitals to those with 
introduce a oroeram of earlv thrombolvtic theraw will be aw.ior~rao~.,c and sureical facilities. There need to be will- 
ineffective and may be uns&cessful o; result in’&reased 
risk for the p&x! or both. 
Risks of tbmmbotytte therapy. The results of all these 
trials are encouraging, but should not be construed as 
evidence that such treatment should be given to all patients 
with an acute coronary syndrome. The use of thrombolytic 
therapy carries with it the risk of serious and occasionally 
fatal bleeding and its effect on reducing mortality in patients. 
other than the early treatment of those with anterior infarc- 
tion. has not been established. Cardiac catheterization per- 
formed. in conjunction with the administration ofthmmboly- 
tic agents results in a high incidence of bematoma at the 
arterial puncture site and ereatlv increases the need for 
blood &sfusion. The mod se&us complication is intra- 
cranial bleeding. In the GISSI trial, without the use of 
routine heparin, the incidence rate of stroke wasO.Z%: in the 
ISAM trial the overall incidence rate was 0.46%. In the TIM1 
trial, with intravenous n-PA. the incidence rate of stroke has 
beenl.6%atadoseof150mggivenover6hand0.6%atl00 
mggivenaverd h (12). Clearly, patients ofadvanced ageand 
those with a history of stroke, transient cerebral ischemia, 
severe hypertension. long-standing diabetes or other condi- 
tions possibly influencing the cerebral vasculature have an 
increased likelihood of intracerebral hemorrhage with the 
use of thrombolytic and associated heparin therapy. 
In view of these introductow remarks. it is evident that 
m&& hod encou&ement by the medical communiry for 
the transport of high risk patients directly to nearby facilities 
that are best able to provide specialized care. This is an 
tmpotiaor divergence from the past when all such patients 
were routinely admitted to the closest tospitd. 
Initial management of acute mycardii bSarrtton in the 
enwgeney department. Perhaps the tu’o greatest impedi- 
mentr to rapid reperfosion therapy are the patient’s misin- 
terpretation or denial of symptoms that prevents him or her 
from seeki& help and the delay from hospital admission to 
mmation of treatmcrd. Several processes often occur in the 
emergency department that serve to delay definitive care. 
These include waiting for the results of routine blocd tests. 
sending the patient for X-ray examination and extensive 
consultation with other physicians, including the patient’s 
practitioner or cardiologist. or both. Couple these events 
witP the often slow, methodical delivery of medications fmm 
the pharmacy. and transporting the patient to the coronary 
care unh lhere reevaluation by a new medical team occws 
before initiating therapy. and delays of 1.5 to 2 h become 
common. In the past, emphasis has been on the accurate 
diagnosis of acute myocvdial infarction (for example, ex- 
te&e and repetitive history taking. multiple physical ex- 
aminations. extensive laboratory examinations including se- 
rial enzyme determinations, ekctmcardiogmm [ECGI and 
chest radiomaph), monitoring. yntiarrhytbmic therapy and 
the use of thrombolytic therapyfor acute mywardial infarc- routine spe&<ty consultation. This compulsive approach to 
lion influencer many aswcts of the evaluation and care of the evaluation of these patients may have been appropriate 
patients with chest pain. In the remaining part of this in an era when therapy was primarily directed at the preven- 
editorial we will review the emergency care of patients with lion of complications. 
suspected acute myocardial infarction and make recommen- Today’s ncrive inrrwentional rhernpy requires o diffewnc 
dations for changes in their evaluation and care to optimize appronch. We believe that there is an urgent need for 
the use of thrombolytic therapy. cardiologists to initiale educational efforts to alter the atti- 
Pwhwpital management of acute mywardisl infnretton. tudes and practices of the hospital’s medical staff. Acute 
Well mataged emergency medical systems that have exten- myocardial infarction rno~t he recognized as a tme medical 
sive physician involvement. in both paramedic training and emergency analogous to that of hemorrhagic shock. Forma- 
supervision, are programs that provide adequate pre- don of a triage and treatmcot team composed of the emer- 
hospital diagnosis, triage and treatme~. To achieve excel- gency department nursing and physician staff and backed UP 
by in-house cardiologists is one way to streamline the care of Futuredevelopmenb. lfthrombolytic thempy is to have a 
tltese patients. The objective of this team is to expeditiously significant impact on acute and postinfarction mortality and 
identify those patients who are most likely to benefit from morbidity, it must he effected early and be widely applicable. 
rewfuiion therapy. Patients with chest pain are to be Given Ihe constraints of time and cost, it is neither eppro- 
screened using a short history, limited physical examination 
and I2 lead ECL The patient with chest pain is then 
classified into one of four categories: II suspected acute 
myocardiel infarction with ST segment elevation, 2) possible 
infarction, 3) chest pain of uncertain origin and 4) nn 
evidence of infarction. This process of initial evaluation and 
triage should be accomplished within I5 to 20 min of the 
patient’s arrival at the hospital. In cases of suspated acute 
myocardial infarction. an additional history is required to 
identify contraindicaiions for thmmbolytic therapy. 
Treatment protoeoi. A uniform protocol should he estab- 
lished for the management of various types of patient8 with 
acute myocardial infarction so that treatment can be initiated 
without delay. A well established pmtocot will prevent 
confusion and reduce the need for timesonsuming consul- 
tation hefore the initiation of therepy, In mmt instances, the 
decision to administer intlavenous;hrombolytic therapy and 
its institution should be caroled out in the emergency depart- 
ment. Because serious complications can occur, informed 
consent should be obtained. If a cardiac catheterization and 
surgical program are available in the hospital. the dditional 
options of early coronary angiogaphy followed by angio- 
plasty or revaacularization w&cry need to be considered in 
some high risk patients, including t&e in cardiogenic shock 
and those with contraindications to lhrombolytic theraw. 
After thrombolytic therapy is initiated, hep&nimt& is 
often recommended to reduce the likelihood of coronary 
reocclusion. 
The manogemenr of venrricular rochycardia or jbrilla- 
lion. or both. before, during and after rhrombolytic therapy 
needs IO bc emphasized. Many patients who have undergone 
closed chest massage and direct cwent cardioversion sus- 
tain significant chest trauma that constitutes a relative con- 
traindication to thrombolytic treatment. In addition, the use 
priate nor practical to rely on a system of care that would 
tmnsport all petients with myocerdial infarction to regiunal 
centers before reperfusion therapy is initiated. The availabil- 
ity of intravenously administered drugs such as ntreptoki- 
nase. urokinase and tissue plasminogen activator makes 
effective repetfusion tbempy appropriate in any hospital 
with an adequately trained 8taiT. There are several areas that 
can be addressed to reduce delay from the onset of symp- 
toms to initiating treatment. In the pre-hospital phase, the 
routine use of a fully portable 12 Iced ECG for diagnosing 
acute myocardial injury and the administration of intrave- 
nous or intramuscular thrombolytic therapy before transport 
to the hospital must be studied. This approach offers the 
opportunity of earlier reperfusion but increases the risk of 
misdiagnosis and misuse of this therapy, which may result in 
serious comptications. Because it is known that very early 
therapy is most effective, careful evaluation of pre-hospital 
thmmbolytic therapy is urgently needed. 
The role of early cardiac carhererization and angioplasry 
needs ro be defined in pcltienrs wirh acure myocardial 
infarcrion. Although residual high grade stenosis is a corn- 
man finding after thrombolytic therapy, questions yet to be 
answered include: should all or only certain types of corn-- 
nary stenoses receive additional t&tment withangioplasty 
and when should such procedures be carried out? The 
management of patients whose thrombosed artery fails to 
reperfuse with intravenous thmmbolytic therapy also needs 
to be defined. At present it is difficult to identify those 
patients without angiography. Even if they are identified, 
those patients in most instances cannot undergo angioplasty 
quickly enough to salvage iscbemic myocardium. 
of central intravenous lines placed during resuscitation also sion rheropy. The most challenging problem will be educat- 
increases the risk of serious hemorrhagic complications. ing and modifying the behavior of patients through atxwopri- 
Therefore. patients who have received cardio&monary 
. 
ate public education programs that encourage early 
resuscitation are at increased risk and. in many instances, evaluation of patients who are at risk for acute myocardial 
should not receive thmmbolytic treatment. On the other infarction. Although organizations such as the American 
hand. patient8 who have had en aneventful direct current Heart Association have made major effmis in public educb 
conlioversion with no chest compression and who have only lion to reduce the time from onset of symptoms to the time 
peripheral intravenous lines in place are suitable for tbmm- 
bolytic therapy. If ventricular fibrillation occurs in a patient 
when patients seek help. the denial of symptoms and delay in 
seeking care are still perhaps the greatest impediments to 
who has received thrombolytic therapy, as in all cases of early treatment. Our current understanding of the oathoohv- 
cardiac arrest, electrical defibrillation should precede chest siology of tmnsmural infarction suggests bat tbe’“wi~d& 
compression if a defibrillator is immediately available. Be- of opportunity” is narrow and that a I h reduction in the 
cause of the pe!ential of intratboracic bleeding. chest com- 
pression should only bz used aft-r defibrillation has failed to 
delay-from onset of symptoms to treatment can make a 
major impact in reducing the morbidity and mortality of 
produce M organized rhythm. myocardial infarction. 
llerammmdationa. Although lhrx is uncertainty aboul reducmg the marbkb~y and mortality of acute myocardial 
methods of optimizing the treatment of parienrs with acute infarction. It IS our hope that the management of patienrs 
myacardial infarction. experience ID date suggests thal WV- during the early phase of acute myacardial infarcdon will 
eral facets of their care need IO be changed. Thcsc include also mpidly evolve so that a large percentage of patients with 
the following: myocardlal infarcuon will be able to receive early coronary 
I. Cord&&f masr brcomr more involvrd br ~ornrn~~- repetiwon therapy. 
niry emergency medico/ syswmr. Paramedics need expert 
training in the recognition of patients with acute myocardial 
infarction. Each emeqzncy medical system dvector needs References 
to reevaluate the delivery of care to Individual? wirh SW 
pared mfarction and the facilities available for their treat- 
I IlMl Sludy timup me thlomtdylll in myaeudirl infa ction ,TIMI,
Illill: phi* I fmlling N E”gl I Mid 1985:31? 93M. 
ment. Each community hospital must work with the director 
of the emergency medical system to assure that high risk 
patients are transported to the facility best able to provide 
for their care with appropriate concern for geographic con- 
siderations and transport time. 
2. Emergency depmmenrr mm srreomlinr rrirrgv and 
trearmen, prorocols of porients wirlr chesr pain. The cardi- 
oloeist must work with the emereencv deoartment dxectar 
to provide a treatment plan for ill g&up; of patients with 
acute myocdrdial infarction. The concept of rapid triage and 
treatment should be analogous to that of a patient admitted 
with severe trauma or hemorrhagic shock. 
should receive tkromholytic lkerapy. Surwal has been the 
major endpoint measured to date. More sensitive indicators 
of benefit an currently being examined. Treatment of pa- 
tients with other types of infarction may benefit from thmm- 
holytic therapy by a reduction in mvwardial infarct size and 
associated ph;si&l disability. Ho&er. this has yet to be 
substantiated. Therefore. ar with ail treatment. patient se- 
lection should be guided by weighing the potential benefits 
against the potential risks of thrombolytic therapy. 
Concluskms. Coronary artery reperfusion therapy is at a 
stage of rapid development and has the potential of markedly 
